Ticker: NVLX/ OTC.QB Mkt. Cap.: 121M

1. 12510 Prosperity Blvd., Suite 310 Silver Spring, MD 20904 Phone (917) 595 2850 Fax (917) 595 2851 Company Overview Stock Information Nuvilex, Inc. (NVLX) is an innovative development stage pharmaceutical company committed to implementing a novel cellulose-based live-cell encapsulation technology to develop treatments for various cancers and for diabetes. The live-cell encapsulation technology employed by Nuvilex encloses living cells in protective “cocoons” the size of the head of a pin - drugs are not encapsulated using this technology. The cell encapsulation technology used by Nuvilex can be classified as a “platform” upon which treatments for different indications may be built. Depending on the type of cells utilized, the encapsulated cells can be employed in developing treatments for serious, debilitating and life-threatening diseases. For example, for cancer, the live-cell encapsulation technology is combined with new or established anticancer drugs Ticker: NVLX/ OTC.QB Mkt. Cap.: 121M *a/o 2/4/14 Recent Close: $0.21* Avg. Vol.: 3,860,640 52 Wk. Range: $0.22 - $0.03 Company Highlights Executive Management • We have an expert team of industry leaders with the vision and drive to successfully unlock the potential of Nuvilex’s products and pipeline. • Exclusive worldwide rights to use live-cell encapsulation technology to develop treatments for cancer and diabetes; poised to deliver multiple products. • An eighty million dollar market cap and an average stock trading volume of over 2,500,000. • A product in late-stage development that employs a well-known cancer drug. • From the core-technology of cellulose-based live-cell encapsulation, multiple treatment areas emerge, encompassing billion dollar markets annually. Nuvilex, Inc. has assembled a team experienced in cancer treatment development and live-cell encapsulation technology. Kenneth L. Waggoner President and CEO Dr. Gerald W. Crabtree Chief Operating Officer Dr. Robert F. Ryan Chief Science Officer Patricia Gruden Chairman of the Board and Chief Financial Officer nuvilex.com Notice Regarding Forward-Looking Statements -- This fact sheet contains forward-looking statements as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this fact-sheet, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of publication of this fact sheet, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this fact sheet are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.

2. Meadows Corporate Park I 12510 Prosperity Blvd., Suite 310 Silver Spring, MD 20904 Phone (877) 958 7616 Fax (917) 595 2851 Company Pipeline Media Coverage Live-Cell encapsulation plus ifosfamide (IFEX®) for pancreatic cancer Article on Nuvilex, Inc. on Sept. 23, 2013, entitled “Biotechs Are Back in Favor: Following a Plethora of Positive Developments” Live-Cell Encapsulation plus Cyclophosphamide for Breast Cancer Live-Cell Encapsulation plus Insulin-producing Cells for Diabetes Nuvilex mentioned in widely read issue on September 11th 2013 in an article titled, “Feds Patented Medical Pot... While fighting it” Live-Cell -cell encapsulation plus cannabinoids from Cannabis for Cannabinoids for Brain and Pancreatic Cancers Medical Marijuana and Major Diseases The use of Cannabis for medicinal purposes dates back over 3,000 years. Originally introduced to western medicine in the early 1840’s, Cannabis has been touted for its reported analgesic, sedative, anti-inflammatory, anticonvulsant, and anti-spasmodic effects. Since the 1970’s, cannabinoids from Cannabis have been recognized for their ability to alleviate nausea and vomiting as well as relieve various types of pain. Since 2001, interest in the anticancer properties of cannabinoids has increased significantly. In vitro, cannabinoids have demonstrated efficacy combating brain, lymphoma, pancreatic, skin, breast, thyroid, colorectal and prostate cancer cells. In animals, cannabinoids reduced tumor growth and metastasis and were shown to be antiangiogenic. In 2006, in a small, early-phase clinical study, THC proved beneficial in treating glioblastomamultiforme, a type of brain tumor, when non-psychoactive doses were used. nuvilex.com Notice Regarding Forward-Looking Statements -- This fact sheet contains forward-looking statements as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this fact-sheet, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of publication of this fact sheet, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this fact sheet are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.

3. Meadows Corporate Park I 12510 Prosperity Blvd., Suite 310 Silver Spring, MD 20904 Phone (877) 958 7616 Fax (917) 595 2851 Live-cell Encapsulation Live-Cell Encapsulation plus Cyclophosphamide for Breast Cancer Nuvilex’sbreast cancer treatment uses the cellulose-based live-cell encapsulation technology with the well-known and widely-used cancer drug cyclophosphamide. Cyclophosphamide (CYTOXAN®) is activated the same way as ifosfamide. Nuvilex aims to treat diabetes by encapsulating insulin-producing cells using the cellulose -based live-cell encapsulation technology, and then implanting them into diabetic patients to serve as a type of artificial pancreas. Live-Cell Encapsulation plus Insulin-producing Cells for Diabetes The cellulose-based live cell encapsulation technology will be used with cannabinoids from Cannabis to develop treatments for some of the deadliest forms of cancer, particularly brain cancer and pancreatic cancer. View of a Single Capsule Live-Cell Encapsulation plus Cannabinoids for Cancer Research done over the past decade in the cancer area with medical marijuana has shown that cannabinoids are effective in the laboratoryand in animals against a wide variety of cancer cells. Studies have shown that cannabinoids can kill cancer cells and prevent the spread and regrowth of established cancers. Live-Cell Encapsulation plus Ifosfamide for Pancreatic Cancer Nuvilex’spancreatic cancer treatment utilizes proprietary cellulose-based live-cell encapsulation technology, together with the long-known and widely used anticancer drug ifosfamide (IFEX®). Ifosfamide, administered intravenously, can cause severe drug-related toxicities, particularly to organs of the urinary tract. The cells encapsulated have high activity of an enzyme that converts ifosfamide into its active (cancer-killing) form. In actual practice, the encapsulated cells are first implanted using radiography, in the blood supply to the pancreas near that organ and thus the tumor itself. Ifosfamide is then administered at 1/3 the normal dose. Doubling of patients’ median survival time and one-year survival rate (as compared to historical data for Gemzar®, the only single-agent treatment approved for advanced pancreatic cancer) were seen in Phase 2 clinical trials, with no serious treatment-related side effects. TUMOR nuvilex.com Notice Regarding Forward-Looking Statements -- This fact sheet contains forward-looking statements as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this fact-sheet, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of publication of this fact sheet, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this fact sheet are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.